Amgen stock: buy or sell?

AMGN stock price: $196.94 0.66% At close on September 20th, 2019

Updated on:
September 20th, 2019


Shares of Amgen grew a tiny 0.66% and closed at $196.94.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.

Should I buy Amgen stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that matches with your character as inversor. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Amgen stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Amgen stock a buy?

Financial institutions and banks post stock ratings everyday. At, we collected 15 ratings published for AMGN stock in the last 30 days.

Is AMGN a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-5Cantor Fitzgeraldn/aNeutral
2019-8-30William Blairn/aHold
2019-8-29JPMorgan Chase & Co.n/aNeutral
2019-8-27Wells Fargo & Con/aMarket Perform
2019-8-27Royal Bank of Canadan/aSector Perform
2019-8-27JPMorgan Chase & Co.n/aHold
2019-8-27BMO Capital Marketsn/aOutperform
2019-8-21Royal Bank of Canadan/aSector Perform
2019-8-16Credit Suisse Groupn/aOutperform
2019-8-12Wells Fargo & CoMarket PerformPositive
2019-7-15Morgan Stanleyn/aOverweight

Amgen stock analysis

Daily outlook

Amgen closed today at $196.94 and grew a tiny 0.66%.

Amgen closed today at $196.94 and grew a tiny 0.66%. Since last August 8th when AMGN stock price broke up the SMA200d line, it gained $14.69 (8.06%). On Aug/9, SMA50d and SMA100d crossed up triggering a rise of 7.07%. On August 30th, AMGN hit new all time highs, pushing higher previous ATH of $210.41 recorded on August 13th. New ATHs are usual entry points for many trading setups as there aren't higher resistences.

AMGN stock chart (daily)

Weekly outlook

After sliding a scary -6.27% in a week last week, Amgen closed this week at $196.94 and inched a slightly fine 0.75%. Late July AMGN skyrocketed an extraordinary 6.34% in just one week.

Amgen stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, AMGN might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last price record Amgen marked late August. Late July AMGN price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

AMGN stock chart (weekly)

Amgen stock price history

Amgen stock went public on June 17th, 1983 with a price of $0.291. Since then, AMGN stock surged a 67,810.30%, with an average of 1,883.60% per year. If you had invested right after AMGN's IPO a $1,000 in Amgen stock in 1983, it would worth $678,103.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Amgen stock historical price chart

AMGN stock reached all-time highs on August/30 with a price of $210.97.

Amgen stock price target is $213.70

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' AMGN stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 13 price targets for AMGN stock:
AMGN stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-5Cantor FitzgeraldReiterates$221.00$230.004.1%
2019-8-29JPMorgan Chase & Co.Raises Target$191.00$198.003.7%
2019-8-27Wells Fargo & CoReiterates$202.00$220.008.9%
2019-8-27Royal Bank of CanadaRaises Target$192.00$206.007.3%
2019-8-27BMO Capital MarketsRaises Target$230.00$240.004.3%
2019-8-21Royal Bank of CanadaRaises Targetn/a$192.00-
2019-8-16Credit Suisse GroupReiterates$202.00$225.0011.4%
2019-8-13OppenheimerRaises Target$210.00$230.009.5%
2019-8-12Wells Fargo & CoReiterates$197.00$202.002.5%
2019-7-15Morgan StanleyLowers Target$211.00$207.00-1.9%
(in average)$206.40$213.704.0%
Moving in a range from $240.00 and $192.00, the price target for AMGN stock is $213.70. In average, analysts' outlook on AMGN price forecast is positive, improving the prediction by a 4.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since April, when Amgen presented its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will update this report.
AMGN earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual sales report draw a beatiful growth of 3.93% to $23,747.00 M USD. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) boosted a 26.69% to 35.35%.

Amgen presents anual results in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Amgen TTM sales up to March 2019 were $23,750.00 and income $8,075.00 M USD. If we compare this TTM figures with the last reported annuality, we can esteem Amgen business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, remained steady a tight 0.01%. In the same way, profit margin (net income/sales) decreased at 35.35%.

AMGN annual Sales and Income evolution
2013$18,670 M-$5,080 M27.2%-
2014$20,063 M7.46%$5,158 M25.7%1.54%
2015$21,662 M7.97%$6,939 M32.0%34.53%
2016$22,991 M6.14%$7,722 M33.6%11.28%
2017$22,849 M-0.62%$1,979 M8.7%-74.37%
2018$23,747 M3.93%$8,394 M35.3%324.15%
TTM $23,750 M0.01%$8,075 M34.0%-3.80%

Quarterly financial results

Amgen reported $5,557.00 million in sales for 2019-Q1, a -10.80% less compared to previous quarter. Reported quarter earnings marked $1,992.00 M with a profit margin of 35.85%. Profit margin inched a 4.90% compared to previous quarter when profit margin was 30.95%. When comparing revenues to same quarter last year, Amgen sales marked a neutral movement and stayed steady a 0.05%.
AMGN quarterly Sales and Income evolution
2017-Q2$5,780 M-$2,150 M37.2%-
2017-Q3$5,780 M0.00%$2,020 M34.9%-6.05%
2017-Q4$5,802 M0.38%$-4,264 M-73.5%-311.09%
2018-Q1$5,554 M-4.27%$2,311 M41.6%-154.20%
2018-Q2$6,059 M9.09%$2,296 M37.9%-0.65%
2018-Q3$5,904 M-2.56%$1,859 M31.5%-19.03%
2018-Q4$6,230 M5.52%$1,928 M30.9%3.71%
2019-Q1$5,557 M-10.80%$1,992 M35.8%3.32%

Amgen ownership

When you are planning to invest in a stock, it's worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Amgen, 0.21% of all outstanding shares are owned by its staff.

Bearish positions for AMGN stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related stocks:

Market cap$118.1 B$106.1 B$23.7 B$43.5 B$82.1 B
Total shares599.7 M1,480.0 M224.2 M184.5 M1,640.0 M
Float shares598.3 M1,480.0 M223.6 M184.0 M1,630.0 M
  - Institutional holdings (%)81.9%71.9%96.8%93.4%75.0%
  - Insider holdings (%)0.2%0.1%0.3%0.5%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Amgen summary

Friday, September 20th, 2019
Day range$195.75 - $199.32
Previous close$195.65
Session gain0.66%
Average true range$3.81
50d mov avg$192.19
100d mov avg$183.57
200d mov avg$185.01
Daily patternlt03a
Weekly pattern lt06a

Amgen performance

To measure stock performance is always good to benchmark with competitors or related stocks. We compared Amgen against AbbVie, Alexion Pharmaceuticals, Biogen, Bristol-Myers Squibb, Celgene, Gilead Sciences, GlaxoSmithKline, and Pfizer in the following table:
ALXNAlexion Pharmaceu...-20.18%-18.85%-13.38%
BMYBristol-Myers Squ...2.37%5.81%-16.97%
GILDGilead Sciences-4.04%5.40%-9.37%

Amgen competitors

We chose a few stocks to conform a list of Amgen competitors to check if you are interested in investing in AMGN:

Latest Amgen stock news